Peterson Caryn, EVP of Regulatory Affairs, has engaged in a series of transactions involving Gossamer Bio (GOSS) shares, as reflected in SEC Form 4 filings. The activity consists entirely of non-monetary transactions—primarily awards (coded "A") and dispositions (coded "D")—with no reported buy or sell value across all 25 filings. The most recent cluster of transactions occurred on March 19, 2026, with 11 awards and 11 dispositions filed on the same day, suggesting administrative adjustments such as vesting events or tax-related dispositions. Earlier activity includes two awards on January 2, 2026, and one on October 1, 2025, all similarly lacking disclosed dollar values.
The pattern indicates Peterson’s holdings in GOSS are subject to periodic equity awards, likely tied to executive compensation, followed by corresponding dispositions, possibly for tax withholding or other administrative purposes. The absence of open-market purchases or sales suggests no discretionary trading bias. All activity is confined to Gossamer Bio, with no transactions in other securities. The filings provide no insight into market-driven decisions, as the transactions appear routine and structured rather than reflective of discretionary investment choices.
AI-assisted summary